Mycophenolate mofetil - instructions for use, dose, side effects, contraindications

Film Sheath: opada white II 85-F-18378 8.0 mg (polyvinyl alcohol-40%, titanium dioxide-25%, macrogol 3350-20.2%, talc-14.8%), iron dye oxide black 0.030 mg.

Each tablet, film coated with 500 mg contains:

active substance: mycophenolate mofetil 500.0 mg;

Excipients: cellulose microcrystalline 225.0 mg, corn starch 50.0 mg, croscarmellose sodium 20.0 mg, magnesium stearate 5.0 mg.

Film Sheath: opada white II 85-F-18378 16.0 mg (polyvinyl alcohol-40%, titanium dioxide-25%, macrogol 3350-20.2%, talc-14.8%), iron oxide red oxide 0.0755 mg.

Description:

Dosage of 250 mg: round flat-cylindrical tablets, covered with a film shell from almost white to light gray.

Dosage 500 mg: round cylindrical tablets, covered with a film shell of light pink color.

Type of tablets on the fracture: homogeneous mass from white to almost white color, surrounded by a film coating corresponding to the dosage of color.

Pharmacotherapeutic group:Immunosuppressive remedy

ATX: & nbsp

L.04.A.A Selective immunosuppressants

Pharmacodynamics:

Immunosuppressant, inhibitor of inosine monophosphate dehydrogenase

Mycophenolate mofetil (MMF) is a 2-morpholinoethyl ester of mycophenolic acid (MPA). IFC is a potent selective noncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDG), which suppresses the synthesis of guanosine nucleotides de novo. The mechanism by which IFC suppresses the enzymatic activity of IMPDG appears to be due to the fact that IFC structurally imitates both the cofactor of nicotinamide dinucleotide phosphate and the catalyzing water molecule. This prevents the oxidation of IMP in xanthose-5-monophosphate - the most important stage of biosynthesis of guanosine nucleotides de novo. IFC has a more pronounced cytostatic effect on lymphocytes than on other cells, since the proliferation of T and B lymphocytes depends very strongly on purine synthesis de novo, while cells of other types can switch to metabolic bypasses.

Efficiency

In clinical studies on the prevention of rejection after kidney, heart and liver transplantation mycophenolate mofetil was prescribed in combination with the following drugs: immunoglobulin antitimocytic, OKT3 (the orthoclone of murine monoclonal antibodies), cyclosporine and glucocorticosteroids.

Prevention of transplant rejection

Adults

Safety and efficacy of mycophenolate mofetil in combination with cyclosporine and corticosteroids were assessed in patients after transplantation of kidney, heart and liver.

Children

Safety, pharmacokinetics and efficacy of the drug Mycophenolate mofetil in combination with cyclosporine and corticosteroids in children after renal transplantation were assessed in an open-label, multicenter study involving 100 children aged from 3 months to 18 years.

Kidney Transplantation

Adults

In combination with glucocorticosteroids and cyclosporine Mycophenolate mofetil statistically significantly (p <0.05) reduced the incidence of treatment failure in the first 6 months after transplantation and histologically proven rejection in the course of therapy at a dose of 2 g / day reduces the cumulative death rate of transplant and mortality for 12 months after kidney transplantation, but at a dose of 3 g per day increases the frequency of premature dropout from the study for any reason.

Children

In children after kidney transplantation in all age groups, the drug intake Mycophenolate mofetil (powder for the preparation of a suspension) was carried out in doses 600 mg / m² twice a day (up to 1 g twice daily).

The overall incidence of histologically proven rejection at 6 months post-transplantation period was comparable to that in adults and was similar in different age groups. The total frequency of graft death (5%) and mortality (2%) for 12 months after transplantation was comparable with the values observed in adults who underwent kidney transplantation.

Heart transplantation

Rejection.

Differences in the frequency of histologically proven rejection, leading to a violation of hemodynamics, in drug groups Mycophenolate mofetil and azathioprine was not.

Survival.

In terms of mortality and repeated transplantations in cardiac transplantation, MMP is superior azathioprine.

Liver transplantation

When conducting a primary analysis (intent-to-treat - all included patients) Mycophenolate mofetil in combination with glucocorticosteroids and cyclosporine is more effective than azathioprine, prevented acute rejection (p = 0.025) and provided the same survival rate as azathioprine.

Preclinical safety data

In doses 2-3 times higher than therapeutic ones during kidney transplantation and 1,3-2 times - in comparison with those in patients after heart transplantation, MMP did not stimulate the formation of tumors and did not affect the fertility of male rats. Two genotoxicity tests (determination of thymidine kinase in murine lymphoma cells and a test with mouse micronuclei) indicated that, at doses having a serious toxic effect, MMF is potentially capable of inducing a chromosomal instability. In other genotoxicity tests (bacterial mutation test, mitotic yeast gene conversion test or chromosome aberration test in Chinese hamster ovary cells) the presence of mutagenic activity in the preparation was not revealed.

In experiments on the fertility and reproductive efficiency of female rats, oral administration of the drug at a dose 0.5 times greater than the systemic dose of 2 g per day after kidney transplantation and approximately 0.3 times the systemic effect of a clinical dose of 3 g per day, recommended after transplantation heart, caused malformations (including anophthalmia, agnathy and hydrocephalus) in the first generation of offspring without any toxic effect on the mother. In subsequent generations of offspring, there were no effects on fertility and reproductive performance.

In teratogenicity studies in rats, there was resorption of fetuses and congenital malformations in the offspring (including anophthalmia, agnates and hydrocephalus in rats and malformations of the cardiovascular system, kidneys, ectopia of the heart and kidneys, diaphragmatic and umbilical hernia in rabbits offspring) with no signs of toxicity action on the mother.

In toxicological studies of MMF on animals, the main lesions were localized in the hematopoietic and lymphoid organs and occurred at a level of system exposure of the drug that is equivalent to or less than the exposure level when taking a clinical dose of 2 g per day, recommended by patients after kidney transplantation. The profile of non-clinical toxicity of MMF coincides with the undesirable phenomena noted in clinical studies in humans, which allowed obtaining safety data that are more significant for the patient population (see section "Side effect").

Pharmacokinetics:

Pharmacokinetic characteristics of MMP were studied in patients who underwent kidney, heart and liver transplantation. In general, in patients after kidney transplantation and heart, the pharmacokinetic profile of the IFC is the same.In the early posttransplant period in patients who underwent liver transplant and received MMP at a dose of 1.5 g, the concentrations of MPC are the same as in patients after kidney transplantation receiving MMF at a dose of 1 g

Suction

After oral administration, fast and complete absorption and complete presystemic metabolism of MMP take place with the formation of an active metabolite - MPA. Bioavailability of MMF in oral administration, according to the area under the curve "concentration - time" (AUCmfk), is in the middle, such with its intravenous administration. After oral administration, the concentrations of MMF in plasma are not determined (below the detection threshold of 0.4 μg / ml).

In the early post-transplant period (up to 40 days after kidney, heart or liver transplantation), the mean values AUCmfk were approximately 30% lower, and maximum concentrations were about 40% lower than in the late post-transplant period (3-6 months after transplantation).

Eating does not affect the degree of absorption of MMF (AUC_IFC) at its appointment on 1,5 g two times a day at patients after a transplantation of a kidney. However, the maximum concentration of IFC when taking the drug during meals is reduced by 40%.

Distribution

As a rule, approximately in 6-12 hours after taking the drug, a secondary increase in the concentration of MPA in the plasma is observed, which indicates a hepatic intestinal recirculation of the drug. With the simultaneous administration of colestyramine AUC_IFC is reduced by about 40%, indicating interruption of hepatic intestinal recirculation.

In clinically significant concentrations, the MPA is 97% bound to plasma albumin.

Metabolism

IFC is metabolized, mainly, under the action of glucuronyltransferase with the formation of pharmacologically inactive phenolic glucuronide MFC (IFPC). In vivo IFPC is converted into a free IFC during hepatic intestinal recirculation.

Excretion

After oral administration of radioactively labeled MMF, 93% of the dose obtained is excreted in the urine, and 6% - with feces. Most (about 87%) of the administered dose is excreted in the urine in the form of MHCI. Minor quantities of the drug (<1% of the dose) are excreted in the urine in the form of an MFC.

Clinically determined concentrations of IFC and IFPC are not removed by hemodialysis.

However, at higher concentrations of IFPC (> 100 μg / ml), some of it can be removed. Bile acid sequestrants such as colestyramine reduce AUC_IFC, interrupting hepatic intestinal recirculation.

Bioequivalence

When examining the bioequivalence of two oral forms of MMP release, it was shown that two 500 mg tablets are equivalent to four 250 mg capsules.

Pharmacokinetics in special clinical cases

In a study with a single dose of the drug (in the group of 6 subjects) in patients with severe chronic renal failure (glomerular filtration rate <25 ml / min / 1.73 m) AUC_IFC was 28-75% more than in healthy volunteers and patients with less severe renal involvement. After taking a single dose AUC_IFC in 3-6 times more in patients with severe renal failure than in healthy volunteers and patients with moderate renal damage, which is consistent with data on renal excretion of IFH.

Studies on the repeated administration of MMF in severe chronic renal failure have not been carried out.

In patients with delayed kidney transplant function after transplantation, the mean AUC_0-12 for IFC is comparable to that in patients in whom the graft began to function after a transplant without delay. In patients with delayed renal transplant function, a transient increase in the free fraction and in the concentration of MPC in the blood plasma can be observed. Probably, the need for correction of the dose of the drug Mycophenolate mofetil these patients do not (see section "Dosage in special cases"). Average value AUC_0-12 for IFPC in plasma was 2-3 times greater than in patients in whom the graft began to function after a transplant without delay.

Patients with the primary non-functioning graft after kidney transplantation, there was an increase in the concentration of IFPC in the blood plasma; the cumulation of IFC, if noted, is much less than in IFAC.

Patients with liver damage. In volunteers with alcoholic cirrhosis of the liver after oral administration of MMP, no changes in the pharmacokinetics of IFC and IFPC have been revealed. The influence of hepatic pathology on this process probably depends on the specific disease. In case of liver disease with a predominance of biliary tract lesions (eg, primary biliary cirrhosis), changes in the pharmacokinetics of IFC and IFPC can not be ruled out.

In patients of childhood (≤18 years) who underwent kidney transplant (in the study n= 55, patients from 1 year to 18 years), after oral administration Mycophenolate mofetil in a dose of 600 mg / m twice a day (up to 1 g twice a day) AUC for IFC is comparable to that in adult patients after kidney transplant receiving a drug at a dose of 1 g twice daily,in the early and late post-transplant period. Values AUC for the IFC did not differ between the age groups in the early late transplantation period.

In elderly and senile patients (≥65 years) pharmacokinetics has not been studied.

Indications:

The drug is used as a combination therapy with cyclosporine and glucocorticosteroids.

Adults and children with a body surface area> 1.25 m² (approximate children's age older than 12 years):

- prevention of acute graft rejection in patients after allogeneic kidney transplantation.

Adults:

- prevention of acute graft rejection in patients after allogeneic heart transplant;

- prevention of acute graft rejection in patients after allogeneic liver transplantation.

Contraindications:

- increased individual sensitivity to MMF, IFC and other components of the drug;

- children with body surface area <1.25 m² (approximate children's age to 12 years);

- simultaneous administration with azathioprine (both drugs depress the bone marrow, their simultaneous administration has not been studied);

- deficiency of hypoxanthine guanine phosphoribosyltransferase (a rare genetic disease due to the hereditary deficiency of hypoxanthine guanine phosphoribosyltransferase - Lesch-Nyen syndrome and Kelli-Zygmiller syndrome).

- the period of breastfeeding;

- pregnancy

Carefully:Diseases of the gastrointestinal tract (in the phase of exacerbation), simultaneous reception of MMF with tacrolimus, sirolimus, with drugs that affect hepatic intestinal recirculation.

Pregnancy and lactation:

Application of the drug Mycophenolate mofetil during pregnancy is contraindicated.

When the drug was used in pregnant female rats and rabbits, adverse effects on the fetus (including developmental defects) were noted; these effects developed with the use of doses that did not have a toxic effect on the mother; and doses lower than those recommended for clinical use. Clinical studies in pregnant women were not conducted.

However, post-marketing use in children of patients treated with MMF in combination with other immunosuppressants during pregnancy revealed congenital malformations, including anomalies in the development of the external ear, maxillofacial area, anomalies in the development of the heart and nervous system (see "Side act"). An increased risk of spontaneous miscarriage in the I trimester of pregnancy is revealed.

A patient planning a pregnancy should not take Mycophenolate mofetil as long as other immunosuppressive drugs are effective. If the patient takes the drug when planning a pregnancy or when a pregnancy occurs, she should be informed of the potential harm to the fetus. MMF can be given to pregnant women only in cases where the potential benefit to the mother exceeds the possible risk to the fetus.

MMP therapy should not be started until a negative pregnancy test result is obtained using the serum or urine analysis method with a sensitivity of at least 50 mIU / mL (no later than 1 week before the start of therapy). Before the initiation of MMP therapy, during the treatment and for 6 weeks after the end of therapy, it is mandatory to use reliable contraceptive methods, even if the woman has a history of infertility (with the exception of the transferred hysterectomy). If abstinence from sexual intercourse is not possible, two reliable contraceptive methods should be used at the same time, since it is potentially possible to reduce the concentration of hormones by oral intake of contraceptives against the background of drug therapy Mycophenolate mofetil. When pregnancy occurs during therapy, the desirability of maintaining pregnancy should be discussed with the doctor.

In rats, MMP is excreted in milk. Whether the MMF is singled out with human milk is unknown. Since many drugs are excreted with human milk, as well as the possibility of serious adverse reactions to MMF in infants, the choice between continuing breastfeeding or taking the drug is made taking into account the importance of treatment for the mother.

Dosing and Administration:

Inside.

Adults

Prophylaxis of kidney transplant rejection

The drug should be taken within 72 hours after the transplant operation. Patients with renal transplants are recommended to take 1 g twice a day (daily dose of 2 g). Although clinical studies have shown that a dose of 1.5 g twice a day (a daily dose of 3 g) is also safe and effective, its benefits in terms of effectiveness in patients after kidney transplantation are not established. In patients receiving 2 g MMF per day, the safety profile was generally better than those receiving a daily dose of 3 g.

Prevention of heart transplant rejection

The drug should be taken within 5 days after the transplant operation. The recommended dosing regimen is 1.5 g 2 times a day (daily dose 3 g).

Prevention of liver transplant rejection

The drug should be taken as early as possible after the transplant operation (depending on the patient's ability to transfer the drug). The recommended dosing regimen is 1.5 g 2 times a day (daily dose 3 g).

Dosing in special cases

When neutropenia (absolute number of neutrophils <1300 in 1 μl of blood), it is necessary to interrupt the treatment of MMF or reduce its dose and carefully observe the patient (see section "Special instructions").

In patients with severe chronic renal failure (glomerular filtration rate less than 25 ml / min / 1.73 m²) outside the nearest post-transplantation period or after therapy for acute or refractory rejection, doses above 1 g 2 times per day should be avoided. Data on patients with severe renal failure who underwent a heart or liver transplant are not available (see section "Special instructions"). Correction of the dose to patients with delayed kidney graft function is not required (see section "Pharmacokinetics in special clinical cases").

Patients who underwent a kidney transplant and had a severe defeat of the liver parenchyma, correction of the dose is not required (see section "Pharmacokinetics in special clinical cases"). Data on patients with severe lesions of the liver parenchyma, who underwent heart transplant, are absent.

In patients elderly and senile age (≥65 years) who underwent kidney transplantation, the recommended dose is 1 g 2 times a day, and after heart or liver transplantation - 1.5 g 2 times a day (see section "Special instructions").

Children:

- prevention of kidney transplant rejection: in patients of childhood over 12 years, with a body surface area of 1.25 - 1.50 m² it is possible to use tablets 750 mg twice a day (daily dose 1.5 g);

- data on the safety and efficacy of the drug in patients of childhood after heart or liver transplantation are absent.

Side effects:

Profile of side effects associated with the immunosuppressive agents is often difficult to establish because of the underlying disease and simultaneous use of many other drugs.

Clinical Trials Data

The main side reactions,associated with the use of MMF in combination with cyclosporine and glucocorticosteroids to prevent rejection of the renal, cardiac or hepatic transplant, are diarrhea, leukopenia, sepsis and vomiting; there are also data on the increase in the incidence of certain types of infections, for example, opportunistic infections (see section "Special instructions").

Malignant neoplasms. As against the combined immunosuppression in general, and with the appointment of MMF as a component of the immunosuppressive regimen, there is an increased risk of developing lymphomas and other malignant tumors, especially the skin (see section "Side effect"), In controlled clinical trials in patients who underwent transplantation kidney, heart or liver and observed for at least 1 year, lymphoproliferative diseases or lymphomas developed in 0.4-1% of patients receiving MMF (in doses of 2 or 3 g / day) in combination with other immunosuppressants. Skin cancer (excluding melanoma) was noted in 1.6-3.2% of patients, malignant neoplasms of other types - in 0.7-2.1% of patients. Three-year data on safety in patients after kidney or heart transplant did not reveal any unexpected changes in the incidence rate of malignant tumors, compared with annual indicators.After liver transplant patients were observed for at least 1 year, but less than 3 years.

Opportunistic infections. The risk of opportunistic infections is increased in all posttransplant patients and increases with an increase in the degree of immunosuppression (see section "Special instructions"). In controlled clinical trials with the administration of MMF (2 or 3 g / day) in combination with other immunosuppressants in patients who were observed for 1 year after kidney transplantation (at a dose of 2 g per day), heart and liver, the most frequent infections were candidiasis of the skin and mucous membranes, cytomegalovirus (CMV) infection: CMV viremia / CMV syndrome (13.5%) and infection caused by the herpes simplex virus. After kidney transplantation, sepsis (usually associated with CMV) was more likely to occur in patients receiving MMF than in the control group. In patients who received IFP at a dose of 3 g, the incidence of sepsis was higher than in patients who received IFP at a dose of 2 g.

Children (3 months - 18 years). The type of adverse reactions and the frequency of their occurrence in a clinical trial with oral administration of 600 mg / m² MMF 2 times a day in children aged 3 months to 18 years (N = 100) did not differ from those in adult patients who received the drug at a dose of 1 g 2 times a day.However, such adverse reactions as diarrhea, leukopenia, sepsis, infections, anemia were more common (≥10%) in children, especially under the age of 6 years.

Have elderly and senile patients (≥65 years) in the treatment of MMF in a combination of immunosuppressive therapy, the risk of certain infections (including tissue invasive forms of manifest cytomegalovirus infection), and possibly also gastrointestinal bleeding and pulmonary edema is higher than in younger patients (see section "Special instructions").

Adverse events noted in ≥10% and in 3-10% of patients receiving MMF in combination with cyclosporine and glucocorticosteroids in controlled studies on the prevention of kidney transplant rejection (3 studies, daily dose of 2 and 3 mg), in a controlled trial of heart transplant and in a controlled liver transplantation study.

		Undesirable effects after transplantation of the night (n = 991) *	Adverse events after cardiac transplantation (n = 289) **	Adverse events after liver transplantation (n = 277) ***
Infectious and parasitic diseases	3-<10%	infection, sepsis	infection, sepsis	infection, sepsis
Violations of the blood and lymphatic system	≥10%	anemia (including hypochromic), leukocytosis, leukopenia, thrombocytopenia	anemia (including hypochromic), leukocytosis, leukopenia, thrombocytopenia, ecchymosis	anemia (including hypochromic), leukocytosis, leukopenia, thrombocytopenia
Violations of the blood and lymphatic system	3-<10%	ecchymosis, polycythemia, bleeding	petechiae, increased prothrombin and thromboplastin time, bleeding	ecchymosis, increased prothrombin time, pancytopenia, bleeding
Disorders from the endocrine system	3-<10%	diabetes mellitus, parathyroid gland diseases (increase of parathyroid hormone level)	diabetes, Cushing's syndrome, hypothyroidism	diabetes
Disorders from the metabolism and nutrition	≥10%		acidosis (metabolic or respiratory), hypervolemia, weight gain
Disorders from the metabolism and nutrition	3-<10%	acidosis (metabolic or respiratory), dehydration, hypervolemia, weight gain	alkalosis, dehydration, gout, hypovolemia, hypoxia, respiratory acidosis, thirst, weight loss, hypervolemia	acidosis, metabolic or respiratory), dehydration, hypervolemia, hypoxia, hypovolemia, weight gain, weight loss
Disturbances from the nervous system	≥10%	dizziness, insomnia, tremor, headache	agitation, anxiety, confusion, depression, dizziness, hypertonia, insomnia, paresthesia, drowsiness, tremor, agitation, headache	anxiety, confusion, depression, dizziness, insomnia, paresthesia, tremor, headache
Disturbances from the nervous system	3-<10%	anxiety, depression, hypertonia, paresthesia, drowsiness	convulsions, emotional lability, hallucinations, neuropathy, thinking disorders, vertigo, dizziness	agitation, convulsions, delirium, dry mouth, hypertonus, hypoesthesia, neuropathy, psychosis, drowsiness, thinking disorders, delirium, agitation
Disturbance of vision	≥10%		amblyopia
Disturbance of vision	3-<10%	amblyopia, cataract, conjunctivitis	visual impairment, conjunctivitis, eye hemorrhages	visual impairment, amblyopia, conjunctivitis
Hearing disorders and labyrinthine disorders	3-<10%		deafness, earache, tinnitus	deafness
Heart Disease	≥10%		arrhythmia, bradycardia, heart failure, pericardial effusion	tachycardia
Heart Disease	3-<10%	Angina pectoris, atrial fibrillation, tachycardia, palpitations	angina, arrhythmias (supraventricular and ventricular extrasystoles, flutter and atrial fibrillation, supraventricular and ventricular tachycardias), cardiac arrest, congestive heart failure, syncope	Atrial fibrillation, arrhythmias, bradycardia, syncope
Vascular disorders	≥10%	increase in blood pressure	decrease and increase of arterial pressure	decrease and increase of arterial pressure
Vascular disorders	3-<10%	lowering of arterial pressure, orthostatic hypotension, thrombosis, vasodilation	orthostatic hypotension, pulmonary hypertension, vasospasm, increased venous pressure	arterial thrombosis, vasodilation
Disturbances from the respiratory system, chest and mediastinal organs	≥10%	cough, dyspnea, pharyngitis, pneumonia, bronchitis	asthma, coughing, dyspnea, pharyngitis, pleural effusion, pneumonia, rhinitis, sinusitis	cough, dyspnea, pharyngitis, pneumonia, pleural effusions, sinusitis, atelectasis
	3-<10%	asthma, pleural effusion, pulmonary edema, rhinitis, sinusitis	apnea, atelectasis, bronchitis, epistaxis, hemoptysis, hiccough, neoplasm, pneumothorax, pulmonary edema, increased sputum separation, voice change	asthma, bronchitis, epistaxis, hyperventilation, pneumothorax, pulmonary edema, candidiasis of the respiratory tract, rhinitis
Disorders from the gastrointestinal tract	≥10%	constipation, diarrhea, indigestion, nausea and vomiting, candidiasis of the oral mucosa, abdominal pain	constipation, diarrhea, indigestion, flatulence, nausea and vomiting, candidiasis of the oral mucosa, abdominal pain	anorexia, constipation, diarrhea, dyspepsia, flatulence, nausea and vomiting, candidiasis of the oral mucosa, hernia, peritonitis, ascites, abdominal pain, bloating
Disorders from the gastrointestinal tract	3-<10%	anorexia, flatulence, gastroenteritis, gastrointestinal bleeding, candidiasis of the gastrointestinal tract, gingivitis, gingival hyperplasia, intestinal obstruction, stomatitis, esophagitis, loss of appetite, gastritis, hernia, bloating	anorexia, dysphagia, gastroenteritis, gingivitis, gingival hyperplasia, melena, stomatitis, esophagitis, loss of appetite, hernia, bloating	dysphagia, gastritis, gastrointestinal bleeding, intestinal obstruction, melena, ulceration of the oral mucosa, esophagitis, rectal damage, gastric ulcer
Disturbances from the liver and bile ducts	≥10%		increased activity of lactate dehydrogenase (LDH), aspartate aminotransferase (ACT), alanine aminotransferase (ALT), bilirubinemia	bilirubinemia, cholangitis, cholestatic jaundice, hepatitis, increased activity of hepatic enzymes (including aspartate aminotransferase (ACT), alanine aminotransferase (ALT))
Disturbances from the liver and bile ducts	3-<10%	impaired liver function, increased concentrations of alkaline phosphatase, hepatitis, increased activity of hepatic enzymes (including aspartate aminotransferase (ACT), alanine aminotransferase (ALT))	impaired liver function, increased concentrations of alkaline phosphatase, jaundice, increased activity of hepatic enzymes (including aspartate aminotransferase (ACT), alanine aminotransferase (ALT))	jaundice
Disturbances from the skin and subcutaneous tissues	≥10%	acne, herpes simplex	acne, herpes simplex, shingles, rash	rash, itching, excessive sweating, labor injuries
Disturbances from the skin and subcutaneous tissues	3-<10%	loss of hair, benign skin tumors, fungal dermatitis, shingles, hirsutism, itching, skin cancer, skin hypertrophy (including actinic keratosis), excessive sweating, skin ulcers, rash	benign neoplasms of the skin, fungal dermatitis, hemorrhages,itching, skin cancer, skin hypertrophy, increased sweating, skin ulcers, labor-injuring wounds, cellulite	acne, fungal dermatitis, hemorrhages, herpes simplex, shingles, hirsutism, benign skin lesions, skin ulcers, vesicle-bulbous rash, cellulitis, scrotal edema, abscesses
Disturbance of musculoskeletal and connective tissue	≥10%	back pain	cramps in the legs, muscle aches, muscle weakness, back pain	back pain
Disturbance of musculoskeletal and connective tissue	3-<10%	pain in the joints, leg cramps, muscle pain, muscle weakness	pain in the joints, pain in the neck	pain in the joints, leg cramps, muscle pain, muscle weakness, osteoporosis
Violation of the kidneys and urinary tract	≥10%	hematuria, renal tubular necrosis, urinary tract infection	impaired renal function (decreased kidney function, increased serum creatinine concentration), oliguria, urinary tract infection	impaired renal function (decreased kidney function, increased serum creatinine concentration), oliguria, urinary tract infection
Violation of the kidneys and urinary tract	3-<10%	albuminuria, dysuria, hydronephrosis, pyelonephritis, frequent urination	dysuria, hematuria, nocturia, renal failure, frequent urination, incontinence and urinary retention	acute renal failure, dysuria, hematuria, renal failure, frequent urination, incontinence
Violations of the genitals, mammary glands	3-<10%	impotence	impotence
General disorders and disorders at the site of administration	≥10%	asthenia, fever, infections, pain in the chest, swelling, swelling, sepsis	asthenia, fever, chills, infections, pain in the chest, swelling, sepsis	asthenia, fever, chills, infections, pain in the chest, swelling, sepsis
	3-<10%	cysts (including lymphocele and hydrocele), facial swelling, flu-like syndrome, malaise, pelvic pain	cysts (including lymphocele and hydrocele), facial swelling, flu-like syndrome, malaise, pelvic pain, pallor of the skin	cysts (including lymphocele and hydrocele), flu-like syndrome, malaise, pain in the neck
Laboratory and instrumental data	≥10%	hypercholesterolemia, hyperglycemia, hyperkalemia, hypokalemia, hypophosphataemia	hyperbilirubinemia, increased residual nitrogen, increased creatinine concentration,increase in the activity of enzymes (lactate dehydrogenase (LDH), aspartate aminotransferase (the ACT), alanine aminotransferase (ALT)) in the blood serum, hypercholesterolemia, hyperglycemia, hyperkalemia, hyperlipidemia, hyperuricemia, hypokalemia, hypomagnesemia, hyponatremia	hyperbilirubinemia, increased residual nitrogen, increase serum creatinine concentration, hyperglycemia, hyperkalemia, hypokalemia, hypocalcemia, hypoglycemia, hypomagnesemia, hypophosphatemia, hypoproteinemia
Laboratory and instrumental data	3-<10%	increased activity of alkaline phosphatase, increased activity of enzymes (gamma glutamyltranspeptidase, lactate dehydrogenase (LDH), aspartate aminotransferase (ACT), alanine aminotransferase (ALT)) in serum, increased serum creatinine concentration, increased serum creatinine concentration, hypercalcemia, hyperlipidemia, hypocalcemia, hypoglycaemia, hypoproteinemia, hyperuricemia	increased activity of alkaline phosphatase, hypocalcemia, chloropenia, hypoglycemia, hypoproteinemia, hypophosphatemia	increased activity of alkaline phosphatase, increase the activity of enzymes (aspartate aminotransferase (the ACT), alanine aminotransferase (ALT)) in the blood serum, hypercholesterolemia, hyperlipidemia, hyperphosphatemia, hyponatremia

* (total n = 1483), ** (total n = 578), *** (total n = 564)

In three controlled studies on the prevention of kidney transplant rejection, the safety profile of MMF in a daily dose of 2 g was slightly better than in a daily dose of 3 g.

Post-marketing application of the drug

On the part of the digestive system: colitis (sometimes cytomegalovirus etiology), pancreatitis, isolated cases of atrophy of intestinal villi.

From the immune system: isolated cases of severe life-threatening infections (meningitis, infective endocarditis), an increase in the incidence of some infections such as tuberculosis and atypical mycobacterial infections.

Cases of progressive multifocal leukoencephalopathy (PML), sometimes fatal, were observed in patients taking mycophenolate mofetil. In reports on these cases, there is information about the presence of additional risk factors for the development of PML in patients, including immunosuppressive therapy and impairment of immunity.

In patients taking mycophenolate mofetil, there were cases of development of nephropathy associated with VC virus (VC virus-associated nephropathy). This infection can lead to serious consequences, sometimes to the death of a kidney transplant.Cases of development of partial red cell aplasia (PKAA) and hypogammaglobulinemia were observed in patients taking mycophenolate mofetil in combination with other immunosuppressive drugs.

Developmental anomalies: cases of fetal development anomalies (including developmental defects of the external ear, malformation of the maxillofacial region, malformations of the heart and nervous system) were registered in patients taking mycophenolate mofetil during pregnancy in combination with other immunosuppressants. Cases of spontaneous miscarriage in the first trimester of pregnancy are recorded.

Other undesirable reactions observed during the post-marketing use of the drug do not differ from the undesirable reactions recorded in controlled clinical trials.

Overdose:

Data on the overdose of MMF were obtained in clinical trials and post-marketing applications. In most cases, no undesirable events have been reported. In case of an overdose of undesirable phenomena, in addition to the below described, it is not revealed.

Expected,that an overdose of MMF probably leads to excessive immunosuppression (as a consequence, to an increased sensitivity to infections) and bone marrow suppression (see section "Special instructions"). In case of development of neutropenia, taking the drug Mycophenolate mofetil the dose of the drug should be discontinued or reduced (see section "Special instructions"). IFC can not be removed from the body by hemodialysis. However, at high concentrations of IFPC in plasma (> 100 μg / ml), small amounts are still output. Preparations that bind bile acids, for example, colestramine, can help eliminate IFC from the body, increasing its excretion.

Interaction:

Acyclovir. With the simultaneous use of MMP and acyclovir, higher concentrations of IFPC and acyclovir in plasma were observed than with the administration of each drug alone. Since plasma concentrations of IFPC, like acyclovir, increase with renal insufficiency, it is likely that these two drugs compete for tubular secretion, which may lead to a further increase in the concentration of both drugs.

Antacids and proton pump inhibitors (IPN). When the drug is used together Mycophenolate mofetil with antacids (aluminum and magnesium hydroxide) and with proton pump inhibitors (lansoprazole and pantoprazole) there was a decrease in the concentration of MPA. However, a significant difference between the rates of graft rejection in patients taking the drug Mycophenolate mofetil simultaneously with drugs IPN and without such, was absent. This conclusion theoretically extends to antacids, as when they are taken simultaneously with the drug Mycophenolate mofetil the concentration of MPC is reduced to a much smaller degree than with simultaneous reception of the drug Mycophenolate mofetil with IPN.

Kolestyramin. After the appointment of a single dose of MMF, 1.5 g of healthy volunteers, previously taking 4 grams of colestyramine 3 times a day for 4 days, there was a decrease AUC_IFC on 40%. Caution should be exercised while using MMF and preparations that affect hepatic intestinal recirculation (see section "Special instructions").

Cyclosporine. Mycophenolate mofetil does not affect the pharmacokinetics of cyclosporine. but ciclosporin affects the hepatic intestinal recirculation of mycophenolic acid (MPA), which can lead to an increase AUC_IFC by about 30% with discontinuation of cyclosporine in patients after kidney transplant receiving mycophenolate mofetil and ciclosporin (compared with patients receiving sirolimus or belatacept with similar doses of the drug mycophenolate mofetil). In contrast, when patients transition from cyclosporine therapy to therapy with immunosuppressants that do not affect hepatic intestinal recirculation of IFC, a change in the exposure of IFC should be expected.

Telmisartan. Simultaneous use with the drug mycophenolate mofetil leads to a decrease in the concentration of MPA by approximately 30%. Telmisartan affects the excretion of IFC by increasing the expression of a gamma receptor activated by peroxisome proliferators, which in turn increases the expression and activity of the gene UGT1A19. There were no clinical manifestations of drug interaction when comparing the incidence of graft rejection and the profile of adverse events in patients receiving the drug Mycophenolate mofetil with or without concomitant therapy with telmisartan.

Ganciclovir. Based on the results of the study with a single oral administration of the recommended doses of MMF and intravenous administration of ganciclovir, taking into account the known effect of renal failure on the pharmacokinetics of MMF (see the sections "Pharmacokinetics in special clinical cases" and "Special instructions") and ganciclovir, it can be assumed that simultaneous application of these two drugs (competing in the process of tubular secretion) will lead to an increase in the concentrations of IFPC and ganciclovir. There is no significant change in the pharmacokinetics of IFC, therefore, it is not necessary to adjust the dose of MMF. If MMF and ganciclovir (or a prodrug thereof, for example, valganciclovir) is prescribed to patients with renal insufficiency, it is necessary to carefully observe patients.

Oral contraceptives. MMF does not affect the pharmacokinetics of oral contraceptives. In a study involving 18 women with psoriasis simultaneous admission for 3 menstrual cycles of the drug Mycophenolate mofetil (1 g 2 times a day) with combined oral contraceptives containing ethinyl estradiol (0.02-0.04 mg) and levonorgestrel (0.05-0.2 mg), desogestrel (0.15 mg) or Gestodene (0.05-0.1 mg), there was no clinically significant effect of the drug Mycophenolate mofetil on the concentration of progesterone, luteinizing hormone (LH) and follicle-stimulating hormone (FSH). In this way, Mycophenolate mofetil does not affect the suppression of ovulation under the influence of oral contraceptives.

However, while taking the drug Mycophenolate mofetil, in addition to oral contraceptives, it is necessary to use other methods of contraception (see the section "Pregnancy and the period of breastfeeding").

Trimethoprim / sulfamethoxazole, norfloxacin, metronidazole. Do not affect the systemic exposure of IFC when administered with one of the antibacterial drugs. But the simultaneous use of the drug Mycophenolate mofetil in combination with norfloxacin and metronidazole reduces AUC_0-48 MFK by 30% after a single dose of the drug Mycophenolate mofetil.

Tacrolimus. With simultaneous application, no effect on AUC and the maximum concentration (C_m_Oh) IFC in patients after liver and kidney transplant.In patients after kidney transplantation, the administration of the drug Mycophenolate mofetil did not affect the concentration of tacrolimus. In patients with stable hepatic transplant AUC tacrolimus after repeated administration of MMP in a dose of 1.5 g twice a day increased by about 20%.

Sirolimus. In patients after kidney transplantation, simultaneous administration of the drug Mycophenolate mofetil and cyclosporine resulted in a decrease in the exposure of MPA by 30-50% compared to patients receiving a combination of sirolimus and the drug Mycophenolate mofetil.

Rifampicin. After correction of the dose, a decrease in the exposure of MFC by 70% (AUC_0-12) in patients after single-stage heart and lung transplantation, it is recommended to monitor the exposure of IFC and dose adjustment Mycophenolate mofetil to maintain clinical effect in a joint appointment.

Ciprofloxacin and amoxicillin in combination with clavulanic acid. In patients after kidney transplantation, on days immediately after oral administration of ciprofloxacin or amoxicillin in combination with clavulanic acid, the minimum concentration of MPA is reduced by 54%.With the continuation of antibiotic therapy, this effect is reduced, and after discontinuation of therapy disappears. The clinical significance of this phenomenon is not known, since a change in the minimum concentration may inadequately reflect the change in the total exposure of the IFC.

Other interactions. With the simultaneous use of probenecid and MMF, monkeys AUCmfkg in plasma in 3 times. Thus, other drugs undergoing tubular secretion can compete with IFPC, which leads to an increase in the concentration of IFPC or another drug in the plasma, which is also subjected to tubular secretion.

Sevelamer. Simultaneous application of sevelamer and IFC in adults and children reduced C_m_Oh and AUC_0-12 IFC by 30% and 25%, respectively. Sevelamer and other phosphate-binding drugs that do not contain calcium should be given 2 hours after taking the drug Mycophenolate mofetilto reduce the effect on IFC suction.

Live attenuated vaccines. Should not be administered to patients in a state of immunosuppression. Antibody formation in response to other vaccines can be reduced (see section "Special instructions").

Special instructions:

As against the combined immunosuppression in general, and with the appointment of MMF as a component of the immunosuppressive regimen, there is an increased risk of developing lymphomas and other malignant tumors, especially the skin (see section "Side effect"). This risk appears to be associated not with the use of any drug per se, but with the intensity and duration of immunosuppression.

As with all patients with an increased risk of skin cancer, exposure to sunlight and ultraviolet rays should be limited by wearing appropriate closed clothing and using sunscreens with a high protective factor. Excessive suppression of the immune system can also increase susceptibility to infections, including opportunistic, sepsis and other fatal infections (see "Side effect" section). Such cases include the reactivation of a latent viral infection, for example, hepatitis B or C, or an infection caused by polyomaviruses. Hepatitis has been reported as a result of the reactivation of hepatitis B or C viruses in patients with hepatitis B or C viruses receiving immunosuppressive therapy.The cases of development of PML, associated with JCvirus, sometimes fatal, were observed in patients taking Mycophenolate mofetil. In reports on these cases, there is information about the presence of additional risk factors for the development of PML in patients, including immunosuppressive therapy and impairment of immunity. In patients with immunosuppression the presence of neurologic symptoms should be carried out by differential diagnosis of PML and recommend consultation of a neurologist. In patients who underwent kidney transplantation and who received Mycophenolate mofetil, there were cases of development of nephropathy associated with VC virus (VC virus- associated nephropathy). This infection can lead to serious consequences, sometimes to the death of a kidney transplant. It is necessary to monitor the status of patients taking MMF to identify patients at risk of developing nephropathy associated with VC virus. With the development of symptoms of nephropathy associated with BV-virus, it is necessary to consider the question of reducing immunosuppression.

The incidence of PKA was observed in patients taking Mycophenolate mofetil in combination with other immunosuppressive drugs. Mechanism of development of PKA in the appointment of the drug Mycophenolate mofetil is not known, nor is the contribution of other immunosuppressants and their combination. In some cases, PKA was reversible after a reduction in the dose of the drug Mycophenolate mofetil or cancellation. However, in patients who undergone transplantation, a decrease in immunosuppression may compromise the graft. Patients receiving MFC should be informed of the need to immediately report to the doctor any signs of infection, bleeding, bleeding, or other signs of bone marrow depression. In the course of MMP treatment, vaccination may be less effective; It is necessary to avoid the use of live attenuated vaccines (see section "Interaction with other drugs"). It is possible to carry out influenza vaccination in accordance with national recommendations.

Since the MMP may be accompanied by adverse reactions from the gastrointestinal tract (ulceration of the gastrointestinal mucosa, gastrointestinal bleeding, gastrointestinal perforation), care must be taken when prescribing MMF to patients with digestive tract diseases in the acute stage.

Since MMF is an inhibitor of IMPDG, it should not be prescribed theoretically from patients with a rare genetically determined hereditary hypoxanthine guanine phosphoribosyltransferase (Lesch-Nyen and Kelly-Sigmiller syndrome).

Care should be taken when switching from combination therapy, including immunosuppressants, that have an effect on hepatic intestinal recirculation of mycophenolic acid (for example, ciclosporin), on therapy with drugs that are devoid of this effect (for example, sirolimus and belatacept) and on the contrary. This transition can lead to a change in the exposure of mycophenolic acid. Caution should be exercised when using drugs of other classes that affect hepatic intestinal recirculation of mycophenolic acid (for example, colestramine) due to their ability to lower the plasma concentration and efficacy of mycophenolate mofetil.

The ratio of risk and benefit of simultaneous use of MMF and tacrolimus or sirolimus is not established.

When using the drug mycophenolate mofetil there were cases of congenital malformations.In patients with severe chronic renal failure, doses more than 1 g 2 times per day should be avoided (see the sections "Pharmacokinetics in special clinical cases" and "Dosing in special cases").

Correction of dose to patients with delayed renal transplant function is not required, but they should be carefully observed (see sections "Pharmacokinetics in special clinical cases" and "Dosing in special cases"). Data on patients who have undergone heart or liver transplant and who have severe renal failure are absent.

In elderly patients, the risk of adverse events may be higher than in younger patients.

Laboratory testing: in the treatment of MMF it is necessary to determine the developed blood formula during the first month weekly, during the second and third months of treatment - twice a month, and then during the first year - monthly. Particular attention should be paid to the possibility of developing neutropenia. Neutropenia can be associated with both MMF intake and other medications, viral infections, or a combination of these causes (see section "Dosage in special cases").If neutropenia occurs (absolute number of neutrophils is less than 1300 in 1 μl), it is necessary to interrupt the treatment of MMF or reduce the dose, while carefully monitoring these patients.

Treatment with the drug

Because MMF in the experiment on rats and rabbits showed teratogenic effect, it is not necessary to break the tablets of mycophenolate mofetil.

Effect on the ability to drive transp. cf. and fur:

When driving vehicles, working with cars and engaging in other potentially hazardous activities, it is necessary to take into account that the drug can cause dizziness and other side effects that can affect the concentration of attention and the speed of psychomotor reactions.

Form release / dosage:

Tablets, film-coated 250 mg, 500 mg.

Packaging:

For 10 tablets in a planar cell box from aluminum foil of printed lacquered and aluminum foil with PVC coating on one side and polyamide coating on the other.

1 contour pack together with instructions for use in a cardboard box.

Storage conditions:

In the dark place at a temperature of no higher than 25 ° C.

Keep out of the reach of children!

Shelf life:

2 years.

Do not use after the expiration date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:LP-003873

Date of registration:03.10.2016

Expiration Date:03.10.2021

The owner of the registration certificate:Emkure Pharmaceuticals Co., Ltd.Emkure Pharmaceuticals Co., Ltd. India

Manufacturer: & nbsp

EMCURE PHARMACEUTICALS Ltd India

Representation: & nbspEMKYUR PHARMACEUTICALS LIMITEDEMKYUR PHARMACEUTICALS LIMITEDRussia

Information update date: & nbsp07.06.2018

Illustrated instructions

Instructions

Mycophenolate mofetil (Mycophenolate mofeyil)